Red-hot generative AI specialist Insilico Medicine has teamed up with another major biopharma player, this time linking up ...
Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer. | Merck & Co.’s almighty ...
As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi has opened a new ...
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish ...
After a 7% increase in revenue for the second quarter, which came on the heels of a 10% gain in Q1, Johnson & Johnson has bumped up its annual sales guidance. The company now projects 2026 revenue at ...
Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program
The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), ...
The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard of care for patients with breast cancer. The regulator is allowing ...
In the second of a new series of interviews with top executives from leading healthcare and comms agencies, Fierce Pharma ...
Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase ...
After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have ...
Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results